In light of a recent case, David Prange (pictured above, left) and Christopher Pinahs, from USA-based law firm Robins Kaplan, provide an Expert View piece containing potentially crucial insights into improving trade secret protection.
In recent years, a greater awareness has emerged for protecting company intellectual property (IP) with complimentary trade secret and patent-protection plans. This awareness is driven in part by the Defend Trade Secrets Act of 2016, which created a federal civil cause of action for trade secret misappropriation, and the increased scrutiny being placed on patents by the America Invents Act and case law addressing patent eligibility.
While trade secret protection is not new, the increased scrutiny on patent protection should push companies to consider a more holistic approach to protecting its IP. Companies should consider developing protection policies for trade secrets and have an action plan in place if a dispute arises. Although patent rights may not be lost by unauthorized use or disclosure, trade secrets potentially are lost if quick action is not taken when an unauthorized disclosure occurs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze